Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination

  • Alina Tscherne, Jan Hendrik Schwarz, Cornelius Rohde, Alexandra Kupke, Georgia Kalodimou, Leonard Limpinsel, Nisreen M.A. Okba, Berislav Bošnjak, Inga Sandrock, Sandro Halwe, Lucie Sauerhering, Katrin Brosinski, Nan Liangliang, Elke Duell, Sylvia Jany, Astrid Freudenstein, Jörg Schmidt, Anke Werner, Michelle Gellhorn Sera, Michael Klüver, Wolfgang Guggemos, Michael Seilmaier, Clemens-Martin Wendtner, Reinhold Förster, Bart L. Haagmans, Stephan Becker, Gerd Sutter, Asisa Volz
  • January 2021, Cold Spring Harbor Laboratory Press
  • DOI: 10.1101/2021.01.09.426032

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1101/2021.01.09.426032

The following have contributed to this page: Dr Bart L. Haagmans